China Unyango lomhlaza wesibindi ngo-2026: Amachiza amva nje kunye neendleko-izibhedlele ezikufutshane nam 

Umhlaza esibindini, ngokukodwa i-hepatocellular carcinoma (HCC), ithumba elibi elivela kwiiseli zesibindi ezifuna ukungenelela ngokukhawuleza, kwiinkalo ezininzi. Ngo-2026, i-China iye yavela njengenkokeli yehlabathi kunyango lomhlaza wesibindi, ibonelela ngendibaniselwano ye-immunotherapy, iindlela zotyando eziphambili njenge-robotic hepatectomy, kunye namaziko okhathalelo abanzi eBeijing. Izigulane ezifuna unyango ngoku zinokufikelela kumachiza asanda kuvunywa afana neLenvatinib edityaniswe ne-TACE kunye ne-novel PD-1 inhibitors, iphucula kakhulu amazinga okuphila kunye nolawulo lwezifo xa kuthelekiswa neminyaka edlulileyo.

Ukuqonda uMhlaza kwisibindi: Iintlobo kunye neMingcipheko yoMngcipheko

Xa uxubusha umhlaza esibindini, kubalulekile ukwahlula phakathi kweendlela eziziiprayimari nezesekondari. Umhlaza wesibindi osisiseko uqala ngaphakathi kwesibindi ngokwaso, kunye ne-Hepatocellular Carcinoma (HCC) ephendula uninzi lwamatyala. Umhlaza wesibindi wesibini, okanye umhlaza we-metastatic, usasazeka kwisibindi usuka kwamanye amalungu afana nekholoni okanye ibele. Iiprothokholi zonyango zohluka kakhulu ngokusekelwe kulo mahluko.

Ukuphuhliswa komhlaza wesibindi osisiseko kudla ngokunxulunyaniswa neemeko zesibindi ezingapheliyo. Amaqela asemngciphekweni omkhulu abandakanya abantu abangaphezu kweminyaka engama-40 ubudala, ngakumbi amadoda, kunye nabasetyhini abangaphezu kweminyaka engama-50 abanembali yosulelo lweHepatitis B okanye C. Ukusetyenziswa kotywala ixesha elide, isifo sikashukela, kunye nembali yentsapho yomhlaza wesibindi nayo iphakamisa amanqanaba omngcipheko kakhulu.

• Iintsholongwane zeHepatitis: Usulelo olungapheliyo ngeHepatitis B (HBV) okanye iHepatitis C (HCV) ngoyena nobangela uphambili kwihlabathi kunye nase China.
• Ukuqina kwesibindi: Ukutshatyalaliswa kwezicubu zesibindi nakwesiphi na isizathu kwandisa amathuba okuba notshintsho olubi.
• Imiba yendlela yokuphila: Ukusetyenziswa kotywala kakhulu kunye nokuphazamiseka kwemetabolism efana nesifo sesibindi esinamafutha angasinxilisayo (NAFLD) ayanda abanegalelo.
• Iityhefu zokusingqongileyo: Ukuvezwa kwi-aflatoxins efumaneka kwiinkozo ezinobumba kunokufaka isandla kutshintsho lwemfuza kwiiseli zesibindi.

Ukufunyaniswa kwangoko kuseyeyona nto ibalulekileyo kwiziphumo eziyimpumelelo. Izikhokelo zonyango zicebisa ukuba abantu abasemngciphekweni omkhulu baye kuxilongwa rhoqo emva kweenyanga ezintandathu. Oku kubandakanya ukubonwa kwe-ultrasound kunye novavanyo lwegazi kumanqanaba e-alpha-fetoprotein (AFP). Ukufunyaniswa kwangethuba kuvumela iindlela zokunyanga ezinje ngoqhaqho loqhaqho okanye utyando lotyando, ngelixa ukuxilongwa kwenqanaba kade kudla ngokukhawulela unyango kukhathalelo lokuthomalalisa okanye unyango lwenkqubo.

Izibhedlele eziPhezulu zoNyango lomhlaza wesibindi eBeijing ngo-2026

I-Beijing isebenza njengendawo yezonyango e-China, ibamba amaziko amaninzi akumgangatho wehlabathi agxile kwi-hepatobiliary oncology. Kwizigulane zamazwe ngamazwe kunye nezasekhaya ezifuna olona khathalelo lungcono umhlaza esibindini, izibhedlele ezithathu zihlala zikwinqanaba eliphezulu ngenxa yezakhono zazo ezibanzi, iziphumo zophando, kunye nobuchule botyando.

Isibhedlele sasePeking Union Medical College (PUMCH)

ISibhedlele saseTshayina seSayensi yezoNyango iPeking Union Medical College Hospital sithathwa ngokubanzi njengeziko eliphambili kumatyala anzima. Isebe Lotyando Lwesibindi lidume ngokusingatha iimeko ezinzima nezintsonkothileyo amanye amaziko anokuthi azibone zingasebenzi. Isibhedlele sikwinqanaba lokuqala kuzwelonke kunyango lokhathalelo olubalulekileyo, olubalulekileyo ekubuyiseni emva kokuhlinzwa kuqhaqho lwesibindi.

I-PUMCH ibonelela ngeqela elidityanisiweyo elipheleleyo le-multidisciplinary (MDT) indlela. Oku kuthetha ukuba oogqirha botyando, ii-oncologists, iingcali ngemitha, kunye neengcali zezifo ziyasebenzisana kwimeko nganye ukwenza isicwangciso sonyango esilolwakho. Eli ziko lineebhedi ezivulekileyo ezingaphezu kwama-2,000 kwaye libambe isikhundla njengeziko elibalulekileyo kwiindidi ezisixhenxe zomgangatho wephondo. Ukuzibophelela kwabo kwimfundo yesigulana kubonakala ngeenzame ezibanzi zenzululwazi yomhlaza.

Isibhedlele esiPhakathi se-PLA yaseTshayina (iSibhedlele sama-301)

Isibhedlele saseTshayina sePLA Jikelele, ngokukodwa iSebe le-Hepatobiliary kunye nePancreatic Surgery, yindawo yamandla kwi-innovation yotyando. Ibekwe kwindawo yesithathu kuzwelonke ekusebenzeni okubanzi kwezibhedlele, iyinkokeli yokufakelwa kwesibindi kunye nokususwa okuyinkimbinkimbi. Isebe likhokelwa ziingcali ezibalaseleyo ezineminyaka engamashumi eminyaka yamava ekuphatheni amathumba anobungozi benkqubo ye-hepatobiliary.

Eli ziko liziko elimiselweyo lolingo lwezonyango lweziyobisi (GCP), elivumela izigulane ukuba zifikelele kulingo lwezonyango lweSigaba sesi-II nese-III kumayeza amatsha. Iseke intsebenziswano yamazwe ngamazwe kunye neYunivesithi yasePittsburgh Medical Centre (UPMC), iququzelele ukutshintshiselwa kweendlela eziphambili zotyando kunye neenkqubo zonyango. Isibhedlele sikwaneziko lophando lwezonyango lwedijithali elisebenzisa iinkqubo zokuxilonga ezincedwa yi-AI ukuze kuphuculwe ukuchaneka.

Isibhedlele saBantu seYunivesithi yasePeking

Isibhedlele saBantu seYunivesithi yasePeking sibonelela ngokhathalelo olukhethekileyo ngeSebe laso loTyando lweHepatobiliary. Ibekwe kwindawo ephezulu kwingingqi yaseMantla eTshayina, idibanisa ukugqwesa koqhaqho lwesintu kunye nonyango lwangoku lwenkqubo. Esi sibhedlele liziko lemfundo enomsila kwiBanga A elinegama le-inshorensi yonyango, nto leyo eyenza ukuba ifikeleleke kuluhlu olubanzi lwezigulane.

Njengabalingane bayo, igxininisa imodeli ye-MDT kwaye ibonelela ngamasebe awodwa abandakanya utyando jikelele, i-oncology ebanzi, i-oncology yamayeza esintu, kunye neradiotherapy. Olu bubanzi beenkonzo buqinisekisa ukuba ingaba isigulane sidinga ukuchithwa okuncinci, i-chemotherapy eqinile, okanye ukunakekelwa kwe-TCM exhasayo, zonke iinkonzo zifumaneka phantsi kophahla olulodwa.

Ukuphumelela kweziyobisi kunye noNyango oluVunyiweyo ngo-2026

Indawo yonyango umhlaza esibindini itshintshe kakhulu ngo-2026 ngokuvunywa kweendlela ezininzi zonyango. Ugxininiso luye lwasuka kunyango lwe-arhente enye ukuya kwiirejimeni ezidibeneyo ezijolise kwiindlela ezininzi ngaxeshanye, okukhokelela kumazinga aphezulu okuphendula kunye nokuphila ixesha elide.

I-Lenvatinib Idibaniswe ne-TACE kunye ne-Immunotherapy

Isiganeko esibalulekileyo senzeke ngoJulayi 2025, ngokuphunyezwa ngokupheleleyo kwi-2026, malunga nokuvunywa kweLenvatinib (Lenvima®). Lo mlomo onamandla we-tyrosine kinase inhibitor (TKI) yomlomo enamandla kakhulu ifumene imvume yesalathisi esitsha: ukudibanisa i-Lenvatinib kunye ne-Pembrolizumab kunye ne-Transarterial Chemoembolization (TACE). Le rejimeni ye-triplet "TACE + Targeted + Immune" yeyokuqala kolo hlobo lwayo kwihlabathi jikelele ukuba yamkelwe ngokusesikweni i-HCC engenametastatic engalungisekiyo.

Idatha yonyango evela kwiSigaba sesi-III sophononongo lwe-LEAP-012 lubonise ukusebenza okumangalisayo. Iqela lonyango elidibeneyo liphumelele i-24-inyanga yokusinda (OS) izinga le-75%, lidlula iqela lokulawula. Ngaphezu koko, i-median progression-free survival (PFS) yandiswe kwiinyanga ze-14.6, ukuphuculwa okuphawulekayo kwiinyanga ze-10.0 ezibonwa kumaqela okunyamekela okusemgangathweni. Le rejimeni ngoku ilukhetho oluqhelekileyo kwizigulana ezinamathumba angenakususwa ngotyando kodwa angekasasazeki kumalungu akude.

I-Finotonlimab kunye ne-Bevacizumab Combination

Olunye uphuculo olubalulekileyo kukwamkelwa kweFinotonlimab (SCT-I10A), i-anti-PD-1 monoclonal antibody ephuhliswe ekhaya. Ekuqaleni kwe-2025, yavunywa ukuba isetyenziswe ngokudibanisa ne-Bevacizumab (SCT510) kwizigulane ezine-HCC engabonakaliyo okanye i-metastatic engazange ifumane unyango lwangaphambili lwenkqubo. Olu nyango lubini lujolise kwi-PD-1 checkpoint kunye ne-vascular endothelial growth factor (VEGF).

Idatha yelizwe langempela kunye nezilingo zeklinikhi zibonisa iNjongo yokuPhendula iNjongo (ORR) ye-33% yolu kudibanisa, iphezulu kakhulu kune-4% ebonwa kumaqela olawulo. Izigulane zafumana i-50% yokunciphisa umngcipheko wokuqhubela phambili kwesifo, kunye ne-PFS ephakathi kweenyanga ze-7.1. Okubaluleke kakhulu, ukusinda okupheleleyo okuphakathi kwafikelela kwiinyanga ze-22.1, ukunciphisa umngcipheko wokufa nge-40% xa kuthelekiswa nemigangatho yangaphambili. Oku kunika ithemba elitsha kwizigulana ezinesifo esikwinqanaba eliphezulu.

I-"O + Y" ye-Dual Immunotherapy Regimen

Ukudibanisa i-Nivolumab (i-Opdivo®) kunye ne-Ipilimumab (Yervoy®), eyaziwa ngokuba yi-regimen ye-"O + Y", iqinise isikhundla sayo njengonyango lokuqala lwe-HCC engabonakaliyo. Ivunywe e-China ekuqaleni kuka-2025, le ndlela yokuhlola i-immune checkpoint inhibitor ivimba zombini iindlela ze-PD-1 kunye ne-CTLA-4. Isebenza ngakumbi kwizigulana ezinokuthi zinganyamezeli iziphumo ebezingalindelekanga ze-TKI okanye zinee-biomarkers ezithile zethumba.

Le rejimeni imele utshintsho oluya kukhetho olungahlawulelwayo lwe-chemotherapy kumhlaza wesibindi ophezulu. Ngokukhulula amajoni omzimba ukuba ahlasele iiseli zomhlaza ukusuka kwii-engile ezimbini ezahlukeneyo, kunokubangela iimpendulo ezihlala ixesha elide kwiseti yezigulana, ezinye zazo ezifumana uxolelo lwexesha elide. Ukufumaneka kolu nyango kwizibhedlele ezinkulu zaseBeijing kuqinisekisa ukuba izigulane zaseTshayina zifikelela kwii-immunotherapies ezifanayo zokusika ezifumaneka e-US naseYurophu.

IiNdlela zoNyango eziBanzi ziyafumaneka eTshayina

Ukunyanga umhlaza esibindini ngo-2026 kunqabile ukuba ibe yindlela yokulinganisa yonke into. Amaziko ezonyango aseTshayina asebenzisa isicwangciso se-multimodal, ukulungelelanisa ukungenelela kwinqanaba lomhlaza, umsebenzi wesibindi esisele, kunye nempilo yonke yesigulane. Umgangatho wangoku wokhathalelo uxhasa imodeli yeQela leNgxoxo yeeNgcaciso ezininzi (MDT).

Ukutshintshwa koTyando kunye noTshintsho lwesibindi

Utyando luhlala lulolona kuphela unyango olunokubakho kumhlaza wesibindi okwinqanaba lakwangoko. Uqhaqho loqhaqho lubandakanya ukususa ithumba kunye nomda wethishu esempilweni. Ukuqhubela phambili kwi-robotic operation kunye neendlela ze-laparoscopic ziye zanciphisa amaxesha okubuyisela kunye neengxaki. Kwizigulane ezinomhlaza wesigaba sokuqala esikhatshwa yi-cirrhosis enzima, ukutshintshwa kwesibindi yeyona ndlela ikhethwayo, njengoko isusa zombini ithumba kunye nesibindi esigulayo.

Ngo-2026, imilinganiselo yokutshintshwa iphuculwe ukuze ibandakanye iiprothokholi ezisezantsi. Izigulana ekuqaleni ngaphandle kweendlela zokufakelwa zinokuthi zifumane unyango lwe-locoregional ukuze zicuthe amathumba, zibenze bafanelekele ukutshintshwa. Amaziko amakhulu eBeijing aqhuba amakhulu ezi nkqubo zinzima minyaka le ngamazinga aphezulu empumelelo.

UNyango lweNdawo yokuXhobisa

Kumathumba amancinci (ngokuqhelekileyo angaphantsi kwe-3 cm) angafanelekanga ukuba enze utyando, ukukhutshwa kwendawo kuyindlela esebenzayo kakhulu. Oku kubandakanya iRadiofrequency Ablation (RFA) kunye neMicrowave Ablation (MWA). Ezi nkqubo zincinci zisebenzisa ubushushu ukutshabalalisa iiseli zomhlaza ngokuthe ngqo. Zihlala zisenziwa ngokuthe ngqo phantsi kwesikhokelo somfanekiso, zifuna kuphela ukuhlala esibhedlele okufutshane.

I-Ablation iya isetyenziswa ngokudibeneyo kunye nolunye unyango. Umzekelo, inokuqeshwa ukunyanga isifo esishiyekayo emva kwe-TACE okanye ukulawula ukuvela kwakhona kwizigulane ebeziqhanyulwe ngaphambili. Ukuchaneka kwemifanekiso yanamhlanje kuvumela oogqirha ukuba bajolise kumathumba ngelixa begcina i-parenchyma esempilweni yesibindi.

Transarterial Chemoembolization (TACE)

I-TACE ihleli ingumgangatho wokhathalelo kumhlaza wesibindi wenqanaba eliphakathi. Le nkqubo ibandakanya ukutofa amayeza echemotherapy ngokuthe ngqo kwi-artery etyisa ithumba, ilandelwa zii-embolic agents ukuthintela ukuphuma kwegazi. Oku "kulamba" i-tumor ye-oksijini kunye nezondlo ngelixa uhambisa umthamo ophezulu wamachiza kwindawo.

Ukuvela kwe-TACE ngo-2026 kubandakanya ukudityaniswa kwayo kunye nonyango lwenkqubo. Njengoko kuphawuliwe ngemvume yeLenvatinib, i-TACE ayiseyiyo i-silo yodwa kodwa iyinxalenye yesicwangciso esibanzi senkqubo. Ubuhlalu beziyobisi kunye nezixhobo ezintsha ze-embolic ziye zaphucula ukusebenza kunye neprofayili yokhuseleko lwale nkqubo, ukunciphisa iimpawu ze-post-embolization syndrome.

Unyango lweNkqubo kunye neRadiation

Kwinqanaba eliphezulu lesifo, unyango lwenkqubo lusisiseko sonyango. Oku kubandakanya unyango olujoliswe kuyo (TKIs), i-immunotherapy (i-checkpoint inhibitors), kunye ne-chemotherapy ngamanye amaxesha. I-arsenal yamachiza iye yanda kakhulu, ivumela imigca yonyango elandelelanayo ukuba umgca wokuqala uyasilela.

Unyango ngemitha, kuqukwa neStereotactic Body Radiation Therapy (SBRT) kunye neProton Beam Therapy, idlala indima ebaluleke kakhulu. Ezi teknoloji zihambisa iidosi eziphezulu zemitha ngokuchaneka okugqithisileyo, ukunciphisa umonakalo kwiithishu zesibindi ezisempilweni. Ziluncedo kakhulu kumathumba abekwe kufutshane nemithambo yegazi emikhulu okanye kwizigulana ezine-portal vein thrombosis.

Uhlalutyo lweendleko: Iindleko zonyango ngo-2026

Ukuqonda iimpembelelo zemali yinxalenye ebalulekileyo yohambo lwesigulana. Iindleko zokunyanga umhlaza esibindini e-China iyahluka ngokubanzi ngokuxhomekeke kwinqanaba lesi sifo, indlela yonyango ekhethiweyo, kunye nexesha lokunyamekela. Ngelixa iindleko zinokubaluleka, ukufakwa kwamachiza amaninzi amatsha kwizikim ze-inshorensi yezonyango yesizwe kuphucule ukufikeleleka.

Iindleko zoTyando

Kwizigulane zesigaba sokuqala ezenza utyando, ixabiso lilonke lisuka kwi-50,000 ukuya kwi-150,000 RMB. Olu qikelelo lubandakanya iimviwo zangaphambi kotyando, inkqubo yotyando ngokwayo, i-anesthesia, kunye nokulaliswa esibhedlele. Iimeko ezintsonkothileyo ezifuna ukuhlala e-ICU okwandisiweyo okanye ulawulo lweengxaki zinokugqitha kolu luhlu.

Utyando lwesibindi lolona khetho lubiza kakhulu. Iindleko ezisisiseko zotyando zidlula i-200,000 RMB. Nangona kunjalo, xa kugxilwa kunyango lwexesha elide lwe-immunosuppressive kunye nokhathalelo olulandelayo, ixabiso elipheleleyo lobomi linokugqithisa i-800,000 RMB. Ngaphandle kotyalo-mali oluphezulu, utyalo-mali lunika elona thuba lihle lokusinda ixesha elide kubagqatswa abafanelekileyo.

Iindleko zoNyango loNgenelelo kunye noNyango lweNgingqi

Iinkqubo zongenelelo ngoncedo ezifana ne-TACE zifikeleleka ngakumbi ngeseshoni nganye, zibiza phakathi kwe-10,000 kunye ne-30,000 RMB. Nangona kunjalo, umhlaza wesibindi uhlala ufuna iiseshini ezininzi ngokuhamba kwexesha, eziqokelela iindleko. Kwizigulane ezineengxaki ze-cirrhosis ezifana ne-ascites okanye ukuphuma kwesisu, ukulaliswa esibhedlele ngenxa yokunakekelwa kwenkxaso kunokuvela kwi-10,000 ukuya kwi-50,000 RMB ngokungeniswa.

Unyango lokukhupha amanzi luwela ngaphakathi kwexabiso elifanayo le-bracket kwi-TACE, kaninzi ukusuka kwi-15,000 ukuya kwi-30,000 RMB ngeseshoni ngokuxhomekeke kubuchwepheshe obusetyenzisiweyo (umzekelo, i-microwave vs. radiofrequency) kunye nenani lamathumba anyangwayo.

Unyango olucwangcisiweyo kunye neendleko zoNyango

Iindleko zonyango lwenkqubo ngokwembali ibingumthwalo, kodwa imbonakalo yomhlaba iyatshintsha. Izigulana ezifike emva kwexesha ezisebenzisa amachiza ajoliswe kuwo afana ne-Sorafenib okanye i-immunotherapies entsha zinokujongana neendleko zonyaka ukusuka kwi-200,000 ukuya kwi-500,000 RMB ukuba ubhatala ngaphandle kwepokotho. Ezinye ii-arhente ezijoliswe kuzo zinokubiza ngaphezulu kwe-30,000 RMB ngenyanga.

Nangona kunjalo, ezininzi zala machiza, kuquka i-Lenvatinib kunye ne-PD-1 inhibitors ezahlukeneyo, zifakwe kwi-China ye-National Reimbursement Drug List (NRDL). Oku kubandakanywa kunciphisa kakhulu iindleko eziphuma epokothweni kwizigulane ezikhuselweyo, ngamanye amaxesha zinciphisa iindleko zenyanga ukuya kumawaka ambalwa e-RMB. Iindleko zonyango lweradiation ziyohluka ngokobuchwephesha, kunye ne-radiation yesiqhelo exabisa i-20,000 ukuya kwi-50,000 RMB, ngelixa unyango lwe-proton oluphezulu lunokugqithisa i-100,000 RMB ngekhosi.

I-ICU kunye neeNdleko zokuKhathalela okuBalulekileyo

Kwizigulane ezinesifo sesibindi sokugqibela okanye ukungaphumeleli kwesibindi, ukhathalelo olunzulu luhlala luyimfuneko. Iindleko zemihla ngemihla kwi-ICU zinokuvela kwi-3,000 ukuya kwi-5,000 RMB. Unyango olukhethekileyo olufana notshintshiselwano lweplasma okanye iinkqubo zenkxaso yesibindi esenziweyo zongeza kwibhili, kunye neeseshini enye exabisa ngaphezulu kwe-RMB eyi-10,000. Ezi ndleko zigxininisa ukubaluleka kokufunyanwa kwangaphambili kunye nokungenelela ukukhusela ukuqhubela phambili kwizigaba ezibalulekileyo.

Uhlahlelo oluThethayo loBuchule boNyango

Ukukhetha indlela yonyango echanekileyo kuxhomekeke ekuvavanyeni ngenyameko yeenzuzo kunye nokulinganiselwa. Olu luthelekiso lulandelayo luchaza amacebo aphambili akhoyo okulawula umhlaza esibindini kwimeko yezonyango yangoku.

Indlela nganye ineenzuzo ezahlukeneyo. Utyando lunika elona thuba liphezulu lokunyanga kodwa luthwala imingcipheko yotyando. I-Ablation ikhuselekile kwaye iyasebenza kwizilonda ezincinci kodwa ngaphantsi kwamathumba amakhulu. I-TACE ilawula ukukhula kwethumba ngokufanelekileyo kumanqanaba aphakathi kodwa ayifane inyange ngokwayo. Unyango olucwangcisiweyo luye lwaguqula ukhathalelo lwesifo esiqhubela phambili, luguqula uxilongo olubulalayo lube sisifo esilawulekayo esilawulekayo kwabaninzi.

Izinto ezingeloncedo nazo kufuneka ziqwalaselwe. Utyando kunye nokufakelwa kwakhona kufuna ixesha elibalulekileyo lokubuyisela kwaye kuthwala ingozi yokopha okanye usulelo. Ukukhutshwa kwesisu akunakuwaphelisa ngokupheleleyo amathumba amakhulu, okukhokelela ekuphindekeni kwendawo. I-TACE inokubangela i-post-embolization syndrome (umkhuhlane, intlungu, isicaphucaphu). Unyango olucwangcisiweyo lunokubangela iziganeko ezinobungozi ezinxulumene nomzimba okanye uxinzelelo lwegazi kunye nokuphendula kwesikhumba sonyawo olusuka kwi-TKIs.

ISikhokelo seNyathelo ngeNyathelo sokufuna unyango eBeijing

Kwizigulane eziceba ukufuna unyango umhlaza esibindini eBeijing, ukukhangela inkqubo yezempilo ngokufanelekileyo kubalulekile. La manyathelo alandelayo achaza inkqubo eqhelekileyo ukusuka kudliwano-ndlebe lokuqala ukuya ekuqalweni konyango.

• Inyathelo 1: Qokelela iiRekhodi zonyango: Hlanganisa onke amaxwebhu akhoyo ezonyango, kubandakanywa i-imaging scans (CT, MRI), iingxelo ze-pathology, iziphumo zovavanyo lwegazi (ingakumbi i-AFP kunye novavanyo lwesibindi somsebenzi), kunye nesishwankathelo sonyango lwangaphambili. Iikopi zedijithali kwidrayivu ye-USB okanye ikhonkco lelifu zicetyiswa kakhulu.
• Inyathelo lesi-2: Khetha isibhedlele kunye neSebe: Khetha isibhedlele esikumgangatho ophezulu njenge-PUMCH, iSibhedlele esiPhambili sePLA, okanye iSibhedlele saBantu seYunivesithi yasePeking. Chonga isebe elithile, ngokuqhelekileyo Utyando lwe-Hepatobiliary, i-Oncology, okanye i-Interventional Radiology, ngokuxhomekeke kwinqanaba elikrokrelwayo.
• Inyathelo lesi-3: Ubhaliso lweNgqesho: Bhalisela idinga nge-app esemthethweni yesibhedlele, iwebhusayithi, okanye ngenkonzo yezonyango. Kwizigulane zamazwe ngamazwe, izibhedlele ezininzi zinikezele amasebe ezonyango kumazwe ngamazwe anceda ngezithintelo zolwimi kunye nolungiselelo.
• Inyathelo 4: Uthethwano lokuqala kunye noPhononongo lwe-MDT: Yima kudliwano-ndlebe apho iingcali ziya kuphonononga ityala lakho. Kwizibhedlele eziphezulu, iimeko ezinzima zivame ukuxoxwa kwintlanganiso ye-MDT ebandakanya oogqirha botyando, i-oncologists, kunye neengcali ze-radiologists ukudala isicwangciso sonyango esidibeneyo.
• Inyathelo lesi-5: Uvavanyo olongezelelweyo: Zilungiselele iimvavanyo ezongezelelweyo ukuhlaziya isimo sakho. Oku kunokubandakanya i-MRI ephuculweyo, i-PET-CT, okanye uvavanyo lwemfuzo ukumisela ukufaneleka kunyango oluthile olujoliswe kuyo okanye ulingo lwezonyango.
• Inyathelo lesi-6: Ukuqaliswa koNyango: Sakuba kuvunyelwene ngesicwangciso, cwangcisa inkqubo okanye uqale amayeza. Ngotyando, kunokubakho ixesha lokulinda ukufumaneka kwebhedi. Kunyango lwamachiza, unyango lunokuqalisa ngokukhawuleza.
• Inyathelo lesi-7: Ukulandelela kunye nokuBeka iliso: Bambelela ngokungqongqo kwishedyuli yokulandelela. Ukubeka iliso rhoqo kubalulekile ukuvavanya impendulo yonyango kunye nokulawula iziphumo ebezingalindelekanga. Uninzi lwezibhedlele zibonelela ngamaqonga e-intanethi okubonisana ngokulandelayo.

Indima yamaQela eZifundo ezininzi (MDT) kukhathalelo lwangoku

Ukuntsokotha kwe umhlaza esibindini ifuna indlela yentsebenziswano. Imodeli ye-MDT ngoku ikumgangatho wegolide kwizibhedlele eziphambili zaseTshayina. Esikhundleni sokubona ugqirha omnye, imeko yesigulane ivavanywa liqela leengcali ezivela kwiingcali ezahlukeneyo. Oku kuqinisekisa ukuba zonke iindlela zonyango ziqwalaselwa phambi kokuba kwenziwe isigqibo.

I-MDT idla ngokubandakanya oogqirha botyando lwe-hepatobiliary, ii-oncologists zonyango, ii-radiologists zongenelelo, ii-oncologists zemitha, ii-pathologists, kunye nabongikazi abakhethekileyo. Ngokomzekelo, ugqirha unokukhuthaza ukutshatyalaliswa, ngelixa i-oncologist icebisa ukunciphisa i-tumor kunye ne-systemic therapy kuqala ukuphucula iziphumo. Imvumelwano ekufikelelwe kuyo yi-MDT ibonelela isigulana ngesona sicwangciso sivakalayo sobunzululwazi kunye nesomntu.

Ngaphaya koko, ii-MDTs ziququzelela ukufikelela kulingo lwezonyango. Ngezibhedlele ezifana neSibhedlele Jikelele se-PLA esisebenza njengeeyunithi ze-GCP, izigulane ekuxoxwe ngazo kwiintlanganiso ze-MDT zinokuchongwa ngokukhawuleza ukuba zibhalise kulingo oluvavanya amachiza amatsha afana ne-Finotonlimab okanye iirejimeni zendibaniselwano yenoveli. Oku kudityaniswa kophando kunye nokusebenza kweklinikhi kukhawulezisa ukufumaneka kweendlela ezintsha zonyango kwabo badinga kakhulu.

Umbono wekamva kunye neeTekhnoloji ezisakhulayo

Ukujonga ngaphaya kwe-2026, ikamva lokunyanga umhlaza esibindini ibonakala ithembisa. Uphando lugxile kakhulu kunyango oluchanekileyo, apho unyango lulungiselelwe ngokusekelwe kwimfuzo yethumba lomntu. I-biopsies yolwelo, efumanisa i-tumor DNA egazini, iya ixhaphake kakhulu ekubhaqweni kwangoko kunye nokujonga impendulo yonyango ngaphandle kweenkqubo ezihlaselayo.

I-Artificial Intelligence (AI) nayo idlala indima yokuguqula. Izibhedlele eBeijing zisebenzisa iinkqubo zokuxilonga ezincediswa yi-AI ukuhlalutya iskena somfanekiso ngokuchanekileyo ngakumbi kunamehlo abantu kuphela. Ezi nkqubo zinokubona iimpawu ezifihlakeleyo zokuphindaphinda kwethumba okanye ziqikelele ukuba ithumba liya kusabela njani kumachiza athile, ukunceda oogqirha ukuba benze izigqibo ezinolwazi ngakumbi.

Ukongezelela, ukuphuhliswa kwe-immunotherapies yesizukulwana esilandelayo kuyaqhubeka. Abaphandi baphonononga ii-antibodies ze-bispecific kunye ne-CAR-T cell therapy eyenzelwe ngokukodwa amathumba aqinileyo njenge-HCC. Ngelixa ubukhulu becala kulingo lwezonyango, obu buchwephesha bubambe amandla okuphucula ngakumbi amanqanaba okuphila kunye nomgangatho wobomi kwizigulana ezinezifo eziphambili.

Ukuqukumbela

Ukukhangela ukuxilongwa kwe umhlaza esibindini lucelomngeni, kodwa inkqubela phambili kwezonyango efunyenwe ngo-2026 inika ithemba elingazange libonwe ngaphambili. I-China, ngakumbi iBeijing, imi phambili kule nkqubela phambili, ibonelela ngofikelelo kwizibhedlele ezikumgangatho wehlabathi, amaqela otyando lweengcali, kunye namachiza aphume phambili amva nje. Ukusuka kwikhono lokunyanga lotyando kunye nofakelo kwizibonelelo zokwandisa ubomi zendibaniselwano entsha ye-immunotherapy efana ne-Lenvatinib kunye ne-TACE kunye ne-Finotonlimab, i-arsenal yonyango inamandla ngakumbi kunangaphambili.

Izigulane ziyakhuthazwa ukuba zifune ukhathalelo kumaziko awodwa asebenzisa indlela yeQela leMultidisciplinary Team (MDT) ukuqinisekisa unyango olubanzi nolwabantu. Ngelixa iindleko zinokwahluka, ukufakwa kwamayeza aphambili kwiinkqubo ze-inshurensi yesizwe kunye nokufumaneka kweendlela ezahlukeneyo zonyango zenza ukuba ukhathalelo olusebenzayo lufikeleleke ngakumbi. Ukufunyaniswa kwangoko kusesona sixhobo sinamandla; ukuhlolwa rhoqo kwabantu abasemngciphekweni omkhulu kunokukhokelela ekufunyanisweni kwesifo kwinqanaba apho unyango olunyanga lunokwenzeka. Ngokuqhubekayo ngokutsha kunye nokugxilwa kwesigulane, imbono yezigulane zomhlaza wesibindi iyaqhubeka nokuphucula unyaka nonyaka.